drugset / Trial / NCT00117624

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy

NCT00117624

Phase 3 Completed Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy of darbepoetin alfa administered using a front-loading approach with subjects receiving standard weekly dosing in the treatment of anemia in subjects with a non-myeloid malignancy and receiving multicycle chemotherapy.

Timeline

Start
2002-12
Primary completion
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 2.25 ug/kg
Subject Darbepoetin alfa Protein / enzyme biologic 4.5 ug/kg

Indications